Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) and MyBiotics Pharma Ltd. announced today they have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. […]
Since the dawn of space exploration, humankind has been fascinated by survival of terrestrial life in outer space. Outer space is a hostile environment for any form of life, but some extraordinarily resistant microorganisms can […]
ADM Ventures, the corporate venture capital arm of ADM (NYSE: ADM), today announced its investment in Seventure’s Health For Life Capital (HFLC) Fund II. HFLC, based in Paris, is a leading venture capital fund dedicated […]
L’Oréal and Micreos announced today the signature of a license agreement to join their expertise in biotechnology and the skin microbiome, the community of bacteria and microorganisms that live on the skin. Under the terms […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a […]
Anyone who has experienced “butterflies in the stomach” before giving a big presentation will be unsurprised to learn there is a physical connection between their gut and their brain. Neuroscientists and medical professionals call this […]
Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, […]
MyBiotics Pharma Ltd., a microbiome therapeutics company, announced today that it was awarded 2.0 million Euros ($2.3 million) by the European Union as part of its Horizon 2020 Program. The grant will support the development of a […]
A new study published this week in the journal Philosophical Transactions of the Royal Society B demonstrates a first attempt at using the methods of ancient bacterial detection, pioneered in studies of past epidemics, to […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. […]
Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million Series A financing and expanded its leadership team. […]